BioSpace News Archive

T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2020. Financial and Operational Highlights Preliminary unaudited fourth quarter 2020 total revenue is expected to be $7.8 million, including product revenue of $5.8 million, representing growth of 155% and 274% respectively, com

Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced that it has commenced an underwritten public offering of $150.0 million of its common stock.

The new year is a great time to evaluate your overall health, but while routine physical exams, eye exams and dental appointments have become commonplace, one area of our health is still oftentimes overlooked: our hearing health.

Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2020 financial results on February 25, 2021 after the market closes and members of its senior management team will host a conference call and webcast on February 26, 2021 at 7:30am ET before the U.S. financial markets open. The dial-in nu

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 financial results on Thursday, February 18, 2021, prior to its earnings call at 8:00 a.m. ET.

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces the following corporate updates.

Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary Shares (“ADSs”), in the United States for trading on The Nasdaq Global Select Market in the United States (the “U.S. Offering”)

Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion of the chPD1 licensing agreement with Longwood University. PD-1 has always been a challenge for CAR-T development. PD-1 is the brakes of the immune system, inhibiting

Envista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its fourth quarter 2020 on Wednesday, February 10, 2021.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS).